A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

被引：2
|
作者：
Topp, Max S. [1 ]
Duell, Johannes [1 ]
Li, Jingjin [2 ]
Jankovic, Vladimir [2 ]
Lowy, Israel [2 ]
Sternberg, David [2 ]
Adriaens, Lieve [2 ]
Peterman, Mary [2 ]
Ambati, Srikanth R. [2 ]
Bannerji, Rajat [3 ]
机构：
[1] Univ Klinikum Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
[3] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-126670
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4007
引用
收藏
页数：4
相关论文
共 50 条
  • [41] A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study of CLN-978 (CD19XCD3XHSA) in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Shouse, Geoffrey P.
    Blum, Kristie A.
    Haydu, Julie E.
    Abramson, Jeremy S.
    Narkhede, Mayur
    Ip, Andrew
    Michaelson, Jennifer S.
    Baeuerle, Patrick A.
    Meetze, Kristan
    Shapiro, Irina
    Shearer, Todd
    Inumerable, Judith
    Jones, Jeff
    Awan, Farrukh T.
    BLOOD, 2023, 142
  • [42] Anti-CD47 Antibody, CC-90002, in Combination with Rituximab in Subjects with Relapsed and/or Refractory Non-Hodgkin Lymphoma (R/R NHL)
    Abrisqueta, Pau
    Sancho, Juan-Manuel
    Cordoba, Raul
    Persky, Daniel O.
    Andreadis, Charalambos
    Huntington, Scott F.
    Carpio, Cecilia
    Giles, Daniel Morillo
    Wei, Xin
    Li, Ying Fei
    Zuraek, Marlene
    Burgess, Michael R.
    Hege, Kristen
    Martin, Alejandro
    BLOOD, 2019, 134
  • [43] C-CAR039, a Novel Anti-CD20/CD19 Bi-Specific CAR T-Cell Therapy Shows Deep and Durable Clinical Benefits in Patients with Relapsed or Refractory (r/r) B-Cell Non-Hodgkin Lymphoma (B-NHL) in Long Term Follow up
    Li, Ping
    Yu, Wen-Juan
    Zhou, Lili
    Yang, Min
    Ye, Shiguang
    Zhu, Judy
    Huang, Jiaqi
    Zhang, Yan
    Li, Lanfang
    Zhao, Jing
    Zhu, Kevin
    Li, Jing
    Zheng, Chengxiao
    Lan, Liping
    Wan, Hui
    Yao, Yihong
    Zhang, Huilai
    Zhou, Daobin
    Jin, Jie
    Liang, Aibin
    BLOOD, 2023, 142
  • [44] RADIOIMMUNOTHERAPY OF REFRACTORY B-CELL LYMPHOMA WITH 131-I-ANTI-B1 (ANTI-CD20) ANTIBODY
    KAMINSKI, MS
    FENNER, M
    ZASADNY, KR
    MILIK, AW
    ROSS, CW
    FRANCIS, IR
    BURGESS, J
    ESTES, J
    CRAWFORD, S
    HODUL, P
    COOK, R
    REGAN, D
    PETRY, N
    GLENN, S
    BUTCHKO, G
    WAHL, RL
    CLINICAL RESEARCH, 1994, 42 (03): : A405 - A405
  • [45] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab
    Sacchi, S
    Federico, M
    Dastoli, G
    Fiorani, C
    Vinci, G
    Clò, V
    Casolari, B
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2001, 37 (01) : 13 - 25
  • [47] a Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (NHL)
    Maddocks, Kami J.
    Cohen, Jonathon B.
    Huang, Ying
    Christian, Beth A.
    Benson, Don M.
    Jones, Jeffrey
    Flowers, Christopher
    Heffner, Leonard T.
    Jenkins, Cynthia
    Sexton, Jennfer
    Neal, Alison
    Kives, Melissa
    Blum, Kristie A.
    BLOOD, 2016, 128 (22)
  • [48] Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
    Shi, Y-K.
    Song, Y.
    Qin, Y.
    Zhou, K.
    Gao, Y.
    Wang, M.
    Wang, P.
    Yin, Q.
    Zhao, F.
    Ma, G.
    Li, F.
    ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
  • [49] Phase I study of CN201, a novel CD3xCD19 bispecific antibody, in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
    Xie, Yang
    Cai, Qingqing
    Liu, Haisheng
    Guo, Ye
    Huang, Wenrong
    Zhang, Mingzhi
    Xia, Yi
    Gao, Yuhuan
    Chen, Xilin
    Tang, Yongjing
    Yin, Shaoning
    Yuan, Shunzong
    Li, Haiying
    Song, Yuqin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Phase I clinical study of Bruton's tyrosine kinase inhibitor (BTKi) HBW-3220 capsules in patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)
    Lee, Ning
    Li, Yingfu
    Mao, Yong
    Liu, Guanfeng
    Li, Jiang
    Liu, Qingchun
    CANCER RESEARCH, 2024, 84 (07)
12345